HOLD UP! ARE WE ABOUT TO TAKE THE WRONG BOOSTER SHOT for COVID-19?

This Winter is going to be possibly the Worse EVER!

I’m all for doing things right. But I’m also WORRIED that Corporate Greed may be lurking around too. You know, pay the Shareholder his Profits. But?

Holy Shit! Take the Wrong Booster? Maybe not Wrong but would another Be A More Potent Weapon against all the Variants? And what about the one the Military is working on?

Are we Racing too fast to get a 3rd Booster SHOT of Pfzier much too quickly? Or Moderna? When we might need to be thinking about is possibly Mixing Our Previous Two Doses with another Vaccine BRAND. I’m like you and I am scared of Monkey Science. But I’ve already got part of The Monkey in me and maybe I want a different tale by getting a different Vaccine Booster from another Company?

It just might be Pfzier and it’s Shareholders are Racing their 3rd Booster Shot before giving a New Study it’s due Evaluation? Will we give it a really decent proper Scientific Review? Or our review?

But Shots For Profit? Money talks. But this Study from Spain is more than something to Think about. Please READ it-

https://www.nature.com/articles/d41586-021-01359-3

Vaccinating people with both the Oxford–AstraZeneca and Pfizer–BioNTech COVID-19 vaccines produces a potent immune response against the virus SARS-CoV-2, researchers conducting a study in Spain have found.

Like when the Covid first appeared, there wasn’t a great deal of Attention given to it outside China. But there is a little something that needs our ATTENTION. Everyone thought China would keep COVID-19 in-house and not escape beyond their Borders. But that didn’t happen. And now a little, but hugely significant Study hasn’t gotten it’s appropriate amount of Limelight so everyone can read it. It’s That Important for everyone that wants the best deal possible. We want the Best put in us. Don’t we?


COVID-19

Common questions

Are the Pfizer and Moderna COVID-19 vaccines interchangeable?

COVID-19 vaccines are not interchangeable. If you received a Pfizer-BioNTech or Moderna COVID-19 vaccine, you should get the same product for your second shot. You should get your second shot even if you have side effects after the first shot, unless a vaccination provider or your doctor tells you not to get it.

But is the Above Statement still True? Or is mixing one of the Above with another Vaccine possible? I’ve got lots of Questions now. Maybe we all should have lots of questions.

https://www.isciii.es/Noticias/Noticias/Paginas/Noticias/Presentaci%c3%b3n-resultados-preliminares-CombivacS.aspx

ISCIII

Logo of the government of Spain - Instituto Carlos III

The combined use of AstraZeneca and Pfizer vaccines against SARS-CoV-2 offers a powerful immune response

| 05/18/2021 |

From left to right: Cristóbal Belda, José Alcamí, Alberto Borobia, Magdalena Campins, Raquel Yotti, Luis Castaño, Jesús Frías, María Teresa Pérez Olmedo and Antopnio Carcas, this Tuesday after the presentation of the results of the CombivacS study.

The Carlos III Health Institute (ISCIII) presented on Tuesday the preliminary results of the CombivacS clinical trial , which is evaluating the response of the immune system (immunogenicity) and the safety associated with the use of a heterologous vaccination regimen (combination of different vaccines) against the SARS-CoV-2 coronavirus. The CombivacS study is the first worldwide to provide data on immunogenicity derived from the combined use of two different vaccines; It is a phase 2 clinical trial, randomized with a 2: 1 ratio, multicenter and adaptive, in which the administration of the Comirnaty vaccine against the SARS-CoV-2 coronavirus (BioNtech / Pfizer) has been analyzed in people under 60 years who had already received a first and only dose of Vaxzevria ( AstraZéneca ); the participants had to be at least in the eighth week post-first dose. 
The first results indicate that this heterologous vaccination regimen is highly immunogenic and does not present problems of post-vaccination reactogenicity different from those already reported in the homologous use (alone) of these same vaccines; that is, the response of the immune system is greatly enhanced after the second dose of the Comirnaty vaccine , while the adverse effects observed are within what is expected, are mild or moderate and are mostly restricted to the first 2-3 days after receiving the vaccine. In no case has a hospital admission secondary to the use of this vaccination regimen been reported within this clinical trial. 
The first person participating in the trial received the reinforcement dose of Comirnaty last Saturday, April 17, at the Cruces University Hospital in Bilbao; In the following 6 days, a total of 673 people entered the study. After randomization, the group that received the second dose of the vaccine was made up of 441 participants, while the control group (which has not received a second dose so far) consisted of 232 people. The mean age in both groups was 44 years and the proportion of women was 56% of the total sample included; the stratification scheme of the trial has made it possible to avoid selection biases in gender, age and center of participation. 

Immunogenicity and reactogenicity data 

The increase in the levels of antibodies and neutralizing antibodies was analyzed in a total of 663 people, using three different techniques. In all cases, the use of a heterologous regimen was shown to potentiate the immune response: antibody titers multiplied by 150 times 14 days after the heterologous booster dose was administered, an effect that was already very evident at 7 days, with an increase multiplied by 123 the initial titles. Additionally, the efficacy of the antibodies generated by the heterologous vaccination was verified by functional tests, which made it possible to demonstrate that the antibodies produced were effective in protecting against SARS-CoV-2. Cellular immunity studies will be available in the next few days. 
Specifically, the antibody titers according to the technique that identifies the SARS-CoV-2 receptor binding region increased from a median of 58 to a value of 9,102, which represented a 150-fold increase in antibody titers, that was still very evident even 7 days after the booster dose that the participants received. In contrast, in the control group the antibody titers remained at levels similar to those obtained 14 days earlier. 
The second of the techniques, which determines antibody levels based on the trimeric protein of the virus, confirmed this immunogenic effect: the people in the experimental group presented antibody levels before treatment of 82 units, which at 14 days reached a median of 3,430 units. This increase, again, was already evident at 7 days; the control group remained at similar figures to those identified at the start of the trial. 
The third of the techniques used explored the efficacy of the antibodies produced. The functional capacity of the antibodies induced by the second dose of Comirnaty was assessed in a neutralization assay with pseudoviruses carrying the SARS-CoV-2 Spike protein. In this assay, the patient’s serum is incubated with the virus and its ability to block infection of cells in culture is tested; the greater the neutralizing, blocking and antiviral capacity of the serum, the higher its ‘titer’, which is defined as the dilution of the patient’s serum that blocks 50% of the infection. This technique showed an increase in neutralizing antibody titers of more than 7 times after the administration of the dose of Comirnaty., said increase being even higher than that described with other homologous vaccination regimens. 
Side effects in the first seven days post-vaccination (reactogenicity) were analyzed according to the severity perceived by the participants (they had to fill in an electronic diary for their follow-up) and by the medical team responsible for each participating center. In short, no side effects led to extra medical attention or hospitalization in any case. All adverse events that were perceived as serious by the participants were explored in real time by the participating center’s physicians, and in no case was this perceived severity confirmed. 
In any case, mild local side effects were common and related to injection site discomfort. The most common systemic side effects were headache (44% of all cases), malaise (41%), chills (25%), mild nausea (11%), mild cough (7%), and fever (2, 5%). In all cases, the side effects are similar to those detected with the homologous vaccination schedules in which these same active principles have been used.

Study of heterologous patterns

The data of the study have been analyzed by an independent Data Safety Monitoring Board that has advised to proceed with the vaccination of people in the control group with the second dose of Comirnaty vaccine , as foreseen by the trial if they fulfilled the hypotheses of immunogenicity and reactogenicity envisaged and communicated the preliminary results to the scientific community and the health authorities.

The data have been presented and explained by  Jesús Antonio Frías , coordinator of the ISCIII Clinical Research Network (SCREN) and head of the Clinical Pharmacology Service, Hospital La Paz, Madrid; Magdalena Campins , Head of the Preventive Medicine and Epidemiology Service, Hospital Vall d ‘Hebron, Barcelona; Luis Castaño González , scientific director of the IIS Biocruces, Hospital de Cruces, Bilbao, and María Teresa Pérez Olmedo , head of the Serology Laboratory, National Center for Microbiology, ISCIII. The director of the ISCIII, Raquel Yotti , opened the session and introduced the data presentation. 

The CombivacS trial is being developed in five hospitals linked to Health Research Institutes such as Cruces in Vizcaya, La Paz and Hospital Clínico San Carlos in Madrid; Vall d’Hebron y Clínic, in Barcelona, ​​being the National Microbiology Center (CNM) of the ISCIII, acts as the central laboratory. After these first preliminary results, the study will monitor and measure the antibodies of the participants over a year. On the other hand, as it is an adaptive trial, the design of CombivacS allows the possibility of including new intervention arms if it is considered appropriate to respond to scientific objectives. 
The advance of these preliminary results responds to the scientific interest generated by the possibility of using combined vaccination regimens. Different European countries, including Germany, France, Sweden, Norway and Denmark, are already recommending combined vaccination regimens in people under 60 years of age who have received a first dose of Vaxzevria(AstraZéneca), while the health authorities of other countries are analyzing the scientific evidence to consider the possibility of incorporating heterologous guidelines in their vaccination strategies. Knowing if it is possible to implement heterologous vaccination schemes using vaccines from different manufacturers would allow the design of more flexible vaccination campaigns, which would speed up the process and facilitate the solution of possible eventualities, such as the impact produced by a brake related to supply processes. . 
Regarding the interpretation of the results of this study, in relation to the possible comparison with other clinical trials, it is necessary to be cautious, since the methodologies and the groups of people treated are not always identical; In any case, with the data already obtained, it can be stated that the immune response observed in CombivacS is in the same range as that described with guidelines based on two doses of the same vaccine. 

This is an amazing New Study released not long ago.

https://www.google.com/amp/s/www.nytimes.com/live/2021/09/16/world/covid-delta-variant-vaccine.amp.html

Covid Live Updates: Idaho Allows Overwhelmed Hospitals to Ration Care If Necessary

Aides at U.S. nursing homes were least likely to be vaccinated, a study shows. President Biden’s plan to roll out additional coronavirus shots next week is in flux as a debate intensifies over whether the doses are needed. In China, the government said it had fully vaccinated 1 billion people.

Here’s what you need to know from New York Times:

Idaho allows overwhelmed hospitals across the state to ration care if necessary.

Attending to a Covid-19 patient at St. Luke’s Boise Medical Center in Boise, Idaho, last month.Credit…Kyle Green/Associated Press

With its hospitals struggling to cope with a flood of patients, Idaho officials activated “crisis standards of care” across the state on Thursday, allowing overwhelmed facilities to ration treatment if needed.

“The situation is dire — we don’t have enough resources to adequately treat the patients in our hospitals

https://www.clintonherald.com/region/third-shot-uk-to-offer-covid-booster-jabs-to-over-50s/article_ffc3eb91-5060-58e7-80c9-119fa614e66e.html

The U.K. announced Tuesday it will offer a third dose of coronavirus vaccine to everyone over 50 and other vulnerable people to help the country ride out the pandemic through the winter months.